
Femtech World is to celebrate game-changing menopause innovations at its global awards event.
The Femtech World Awards, now in their third year, celebrates the brightest lights in women’s health innovation.
The event celebrates some of the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.
The winner of the Menopause Innovation of the Year award will have shown exceptional innovation in addressing the health, wellbeing and quality-of-life needs of people navigating perimenopause, menopause and beyond.
Consideration will be given to impact, inclusivity accessibility and the ability to break stigma while delivering meaningful solutions.
This award celebrates those leading the way in redefining how menopause is understood and supported across healthcare and society.
The award is sponsored by Cross-Border Impact Ventures (CBIV) – an impact venture capital firm on a mission to revolutionise venture investing in health technology.
CBIV invests in early-growth stage health technology companies commercialising medical devices, diagnostics, therapeutics, and digital health innovations and leveraging cutting-edge technologies like Artificial Intelligence (AI) and Machine Learning (ML).
All innovations CBIV finances are relevant to women’s, children’s, and adolescents’ health and located in North America and Europe, with the ability to scale technologies to emerging markets.
CBIV is driven by the belief that good health should not be restricted by gender, age, race, wealth, or borders and seeks to expand access to their portfolio’s world class technologies inclusively and globally.
Annie Thériault, managing partner, Cross-Border Impact Ventures , said: “Being part of the FemTech World Awards gives us a front-row seat to the most exciting breakthroughs in women’s health.
“It’s a powerful way to stay connected to the pulse of innovation and the future of care.”
Find out more about the awards and enter for free here.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









